uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes
Show others and affiliations
2011 (English)In: Clinica Chimica Acta, ISSN 0009-8981, E-ISSN 1873-3492, Vol. 412, no 23-24, 2063-2069 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: Coumarin anticoagulants such as warfarin are used to treat and prevent thromboembolic events in patients. The required dosage is difficult to predict and the risk of over or under anticoagulation are dependent on several environmental and clinical factors, such as concurrent medication, diet, age and genotype for polymorphisms in two genes CYP2C9 and VKORC1.

METHODS: A novel fluorescent PCR genotyping assay using HyBeacon® probes, was developed to enable clinical staff to genotype the CYP2C9*2 and CYP2C9*3 alleles and the VKORC1 G-1639A polymorphism directly from unextracted blood samples. A prototype PCR instrument, Genie 1, suitable for point of care use was developed to carry out the assays. The panel of tests was validated by analysing blood samples from 156 individuals and comparing genotypes with data obtained using DNA samples from the same individuals. The accuracy of genotypes obtained with the Genie 1 was compared against results from well validated real time PCR and PCR-restriction fragment length polymorphism analysis.

RESULTS: Identical results were obtained for the newly developed HyBeacon® method and the validation method in all cases except for one where no result was obtained for the VKORC1 polymorphism on the Genie instrument. The samples used for validation represented all six possible *2 and *3 allele-related CYP2C9 genotypes and all three VKORC1 G-1639A genotypes.

CONCLUSIONS: We observed excellent accuracy for the newly developed method which can determine genotype in less than 2 h.

Place, publisher, year, edition, pages
2011. Vol. 412, no 23-24, 2063-2069 p.
Keyword [en]
Warfarin, Phenprocoumon, Acenocoumarol, CYP2C9, VKORC1, Point of care genotyping
National Category
Pharmacology and Toxicology Biomedical Laboratory Science/Technology
Identifiers
URN: urn:nbn:se:uu:diva-163037DOI: 10.1016/j.cca.2011.07.013ISI: 000296686100008PubMedID: 21827742OAI: oai:DiVA.org:uu-163037DiVA: diva2:462507
Funder
Swedish Research Council
Available from: 2011-12-07 Created: 2011-12-07 Last updated: 2017-12-08

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Kohnke, HugoWadelius, Mia

Search in DiVA

By author/editor
Kohnke, HugoWadelius, Mia
By organisation
Clinical PharmacologyClinical pharmacogenomics and osteoporosis
In the same journal
Clinica Chimica Acta
Pharmacology and ToxicologyBiomedical Laboratory Science/Technology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 373 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf